SUBCUTANEOUS BORTEZOMIB IN PATIENTS OVER 75 YEARS WITH MULTIPLE MYELOMA

被引：0
作者：
Violeta, Martinez-Robles [1 ]
Belen, Ballina [1 ]
Seila, Cerda [1 ]
Filomeno, Rondon [1 ]
Natalia, De Las Heras [1 ]
Jose-Antonio, Rodriguez-Garcia [1 ]
Fernando, Escalante [1 ]
机构：
[1] Complejo Asistencial Univ Leon, Leon, Spain
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-003
引用
收藏
页码：302 / 302
页数：1
相关论文
共 50 条
  • [21] Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma
    Podar, Klaus
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2014, 6 : 15 - 23
  • [22] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Kamimura, Tomohiko
    Miyamoto, Toshihiro
    Takashima, Shuichiro
    Yokota, Noriko
    Chong, Yong
    Ito, Yoshikiyo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (04) : 525 - 527
  • [23] SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB: A REAL-LIFE STUDY ON MULTIPLE MYELOMA PATIENTS
    Mangiacavalli, S.
    Cocito, F.
    Ferretti, V.
    Cartia, C.
    Cazzola, M.
    Corso, A.
    HAEMATOLOGICA, 2015, 100 : 519 - 519
  • [24] SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A SINGLE INSTITUTION
    Lopez San Roman, I.
    De Miguel, D.
    Golbano, N.
    Diaz Morfa, M.
    Morales, D.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    Pinedo, B.
    HAEMATOLOGICA, 2012, 97 : 603 - 603
  • [25] DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
    Cerchione, C.
    Nappi, D.
    Migliaccio, I.
    Salvatore, D.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2016, 101 : 801 - 801
  • [26] Bortezomib for the treatment of multiple myeloma patients
    Green, C.
    Bryant, J.
    Takeda, A.
    Cooper, K.
    Clegg, A.
    Smith, A.
    Stephens, M.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 29 - 33
  • [27] Efficacy and safety of subcutaneous bortezomib versus intravenous bortezomib in patients with multiple myeloma: a systematic review and meta-analysis
    Zhang, Shilong
    Li, Jing
    Liu, Peng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (02): : 445 - +
  • [28] SAFETY AND EFFICACY OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB IN PATIENTS WITH NEWLY ELDERLY DIAGNOSED MULTIPLE MYELOMA
    Bacchiarri, F.
    Nozzoli, C.
    Antonioli, E.
    Staderini, M.
    Barone, F.
    Guarrera, A.
    Messeri, M.
    Coltro, G.
    Grieco, P.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 167 - 167
  • [29] Prospective comparison of subcutaneous vs intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and
    Moreau, P.
    Coiteux, V.
    Hulin, C.
    Facon, T.
    van de Velde, H.
    Acharya, M.
    Harousseau, J. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 158 - 158
  • [30] Prospective comparison of subcutaneous to intravenous administration of bortezomib in patients with multiple myeloma: Pharmacokinetics, efficacy and toxicity
    Moreau, P.
    Coiteux, V.
    Hulin, C.
    Facon, T.
    van de Velde, H.
    Acharya, M.
    Harousseau, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345